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Abstract
Background: Convincing evidence suggests that the risk of colorectal cancer (CRC) is increased by the typical
Western diet characterized by high consumption of red and processed meat. In addition, some epidemiological
studies suggest a reduction in the risk of CRC associated with fish consumption. The role of the gut microbiome
in this diet-associated risk is not well understood.
Methods/design: This is a randomized parallel open clinical trial comprising a total of 150 clinically healthy subjects
randomly assigned to three groups: a meat-based diet of which 4 portions per week are red meat (1 portion = 150 g),
3 portions per week are processed meat (1 portion = 50 g), and 1 portion per week is poultry (1 portion = 150 g), for a
total amount of 900 g per week of meat and derivatives; a meat-based diet supplemented with alpha-tocopherol; and
a pesco-vegetarian diet excluding fresh and processed meat and poultry, but which includes 3 portions per week of
fish for a total amount of 450 g per week. Each intervention will last 3 months. The three diets will be isocaloric and of
three different sizes according to specific energy requirements. Anthropometric measurements, body composition, and
blood and fecal samples will be obtained from each participant at the beginning and end of each intervention phase.
The measure of the primary outcome will be the change from baseline in DNA damage induced by fecal water using
the comet assay in a cellular model. Secondary outcome measures will be changes in the profile of fecal microbiomes,
global fecal and urinary peroxidation markers, and neoplastic biomarkers.
Discussion: Although epidemiological data support the promoting role of meat and the possible protective role of
fish in colon carcinogenesis, no study has directly compared dietary profiles characterized by the presence of these
two food groups and the role of the gut microbiome in these diet-associated CRC risks. This study will test the effect
of these dietary profiles on validated CRC risk biomarkers.
Trial registration: ClinicalTrials.gov, NCT03416777. Registered on 3 May 2018.
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Background
Colorectal cancer (CRC) is the second leading cause of
cancer death in Europe. The geographical variation of
incidence shows how environmental factors, particularly
eating habits, play an important role in this disease [1].
Compelling evidence suggests that the risk of CRC is in-
creased by consumption of red and processed meat as
well as decreased by foods containing dietary fiber [2].
Although epidemiological studies suggest a reduction in
the risk of CRC associated with fish consumption, the
evidence for this link is still limited [2]. For non-starchy
vegetables and fruits, although there is evidence indica-
tive of a protective effect, this evidence is similarly con-
sidered limited and therefore less convincing than the
promoting effect of red and processed meat [3].
Several hypotheses have been proposed to explain the
association between red and processed meat and CRC:
meat-based diets contain carcinogens formed during
cooking but also lipid peroxidation and N-nitroso com-
pounds whose formation is catalyzed by heme iron
present in the colon following red and processed meat
consumption [4]. Recent experimental studies [4, 5], epi-
demiological studies on the E3N cohort [6], and the ran-
domized, double-blind, placebo-controlled SU.VI.MAX
study [7] have demonstrated respectively the central role
of heme iron and iron-induced peroxidation. On this
basis, it has also been shown that antioxidants, in par-
ticular tocopherol, may help prevent colon cancer by de-
creasing the formation of mutagens arising from the
peroxidation of fecal lipids, by decreasing oxidative
stress in the epithelial cells of the colon, and by molecu-
lar mechanisms that influence cell death, cell cycle, and
transcriptional events [6, 7]. Moreover, recent data have
shown that consumption of a heme iron-enriched diet
results in the alteration of gut microbiota consumption
and function in rats that was associated with gut barrier
defects, and that the gut microbiota is involved in heme-
induced peroxidation [8]. On this basis, it has been
reported that this microbiota is necessary for heme-
induced hyperplasia and epithelial hyperplasia [9].
Despite these results, the role of the intestinal micro-
biome in determining the risk of cancer associated with
red and processed meat has not yet been clarified.
The microbial fermentation of plant foods, associated
with a low risk of CRC, increases intestinal short chain
fatty acids (SCFAs), including butyrate, which has an-
tineoplastic activity through its inhibition of histone
deacetylase and the promotion of apoptosis [10], and
also increases activated microbial phytochemicals,
such as polyphenols with anti-inflammatory and anti-
oxidant properties [11]. Consequently, it is known
that diet influences the composition of the intestinal
microbiome, as described by our group in a study on
a rural human population [12], and the emerging
evidence implies an involvement of the intestinal
microbiota in CRC.
Cohort studies with subjects who consume various
types of diets (e.g., omnivores, vegetarians, vegans) sug-
gest that the diet alters the intestinal microbiome and
the cytotoxic and genotoxic activities of the luminal co-
lonic content [13]. However, although the association
between the intestinal microbiota and the CRC is con-
ceptually interesting, these results do not help to explain
the mechanisms underlying the modulation of the intes-
tinal microbiota by diet and the consequent impact on
CRC risk.
We aimed to design this randomized, open, parallel
clinical trial that will test whether diet effects on CRC
risks are mediated by interaction with the intestinal
microbiota and whether meat-based and pesco-
vegetarian diets differentially modulate CRC risk bio-
markers in clinically healthy subjects.
Methods/design
Study design
The randomized, open, parallel clinical trial will be con-
ducted at the Unit of Clinical Nutrition of the Careggi
University Hospital in Florence, Italy. The study design
follows the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) guidelines (see Fig. 1
and Additional file 1).
Eligibility criteria
Clinically healthy subjects (both sexes), aged 18–50
years, will be included in the study. The study popula-
tion will be selected between these particular ages be-
cause after 50 years the risk of CRC shows a significant
increase in incidence.
Exclusion criteria are the presence of current illness or
unstable conditions that need medical supervision,
current or recent (past 2 months) use of antibiotics or
probiotics, pregnancy or intention to become pregnant
in the next 12 months, lactation, smoking habit, and
current or recent (past 2 months) adoption of vegetarian
or vegan diets.
Interventions and participant timeline
This clinical randomized study will use a parallel design
with three intervention periods. After a 2-week run-in
period, the eligible participants will be randomly
assigned to three diets differing in the associated CRC
risk: a meat-based diet (MBD, high risk), a nutritional
control of a high-risk diet (MBD with alpha-tocopherol,
MBD-T, presumably medium risk), and a pesco-
vegetarian diet (PVD, low risk). Each diet period will last
3 months. The MBD will include 4 portions per week of
red meat (1 portion = 150 g), 3 portions per week of
processed meat (1 portion = 50 g), and 1 portion per
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week of poultry (1 portion = 150 g), for a total amount of
900 g per week of meat. The MBD-T with a nutritionally
controlled risk will be similar to the MBD but supple-
mented with 100 mg/day of alpha-tocopherol. The PVD
will exclude fresh and processed meat and poultry but
will include 3 portions per week of fish, excluding shell-
fish (1 portion = 150 g), for a total amount of 450 g per
week. The diets will contain other sources of proteins
(e.g., eggs, dairy, legumes/beans), will be isocaloric, and
will derive about 30% of energy from fats, 15% to 20%
from proteins, and the rest from carbohydrates (mainly
complex). No meals or supplements will be provided.
Participants will prepare their meals or eat at restau-
rants. For all the diets, alcoholic beverages will be lim-
ited to one per day for women and two per day for men.
Participants will be asked not to alter their physical exer-
cise habits during the study.
The standardized baseline assessment for the interven-
tion and control groups will include a questionnaire
regarding demographic information, risk factors, and co-
morbidity. Furthermore, at the baseline visit, participants
will be instructed on the objectives and methods of the
clinical trial. Subjects who agree to participate in the
study, after signing the informed consent, will be in-
cluded and randomly divided into three groups, each
assigned to consume the MBD, MBD-T, or PVD. Each
participant will have to complete a 3-day dietary record
(for 2 weekdays and a weekend day) before starting, and
a dietician will analyze all 3-day dietary records using a
country-specific food-nutrient database.
The study procedures are depicted in Fig. 2. There will
be two clinical evaluations of the study population: at
the beginning (Time 0) and at the end of the dietary in-
terventions (Time 1).
Outcome measures
Primary outcome
The primary outcome will be DNA damage (strand
breaks and oxidized bases) in a human colon cancer cell
line (HT29) exposed to fecal water. Genotoxic activity of
fecal water will be determined by the comet assay, which
evaluates the induction of DNA strand breaks and oxi-
dized DNA bases upon exposure of the cells to fecal
water [14]. The metric used will be changes in means
from Time 0 to Time 1. Image acquisition will be per-
formed with the Comet Assay IV software (Perceptive
Instruments, UK). For each fecal water sample there will
be a genotoxicity index (a single figure representing the
mean area of the Comet tail [the percentage of DNA in
the tail] measured in 100 cells). This figure will then be
used in multivariate analyses to predict the potential op-
erational taxonomy units (OTUs) measured using meta-
genomics approaches, potentially providing specific
metabolic functions associated with the risk of neoplastic
Fig. 1 Time schedule of enrollment, interventions, and assessments for participants
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transformation [15, 16]. For this reason, this outcome
was selected as the primary outcome of the study. In a
previous study [14], fecal water activity markers were af-
fected by specific dietary components linked with CRC
risk such as red meat, and were sensitive to dietary sup-
plementation with chemopreventive agents.
Secondary outcomes
Secondary outcomes will be measured in stool samples,
blood, and urine. The metric used will be changes in
means from Time 0 to Time 1. Regarding stool samples,
we will evaluate the following:
 Fecal microbiota profile (fungi and bacteria) and
fecal targeted metabolomic profile (SCFAs, amino
acids, and secondary bile acids) changes from
baseline. Total microbial DNA will be extracted
from the participants’ faces using repeated bead-
beating. The V3 and V4 hypervariable regions of the
16S rRNA gene for bacteria and the internal
transcribed spacer (ITS1–4) for fungi will be
sequenced on an Illumina MiSeq platform, following
the Illumina protocol for 16S Metagenomic
Sequencing Library Preparation. SCFAs, amino
acids, and secondary bile acids will be measured by
mass spectrometry (MS) on fecal samples. SCFAs
will be analyzed using gas chromatography (GC)-
MS, and bile acids by high-performance liquid
chromatography (HPLC)–MS/MS analysis based on
retention times and accurate masses of metabolites.
The metabolites will be targeted and will be reported
in absolute concentration. The amino acids will be
analyzed by a combination of ultra high-
performance liquid chromatography (UHPLC)-based
hydrophilic interaction liquid chromatography
(HILIC) and hybrid quadrupole time-of-flight (Q-
Tof™) MS. The outcome measure will permit us to
describe if and how the microbiome and the relative
metabolomic profiles in clinically healthy subjects
consuming three diets differing in their content of
meat, meat products, and fish will change from
baseline level. Numerous pathogenic microbes are
known to promote CRC, but there is still limited
evidence describing the impact of the diet on the
composition of the fecal microbial populations and
relative metabolites [17].
Fig. 2 Organization of the intervention study
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 Fecal water untargeted metabolomic profile changes
from baseline. On selected samples, based on fecal
water genotoxicity results, we will perform
untargeted metabolomics by using one-dimensional
(1H) nuclear magnetic resonance (NMR)
spectroscopy. The outcome measure will permit us
to analyze the qualitative change of fecal waters
(bioavailable parts of fecal material) and potentially
to identify new biomarkers associated with CRC risk.
 Mutagenicity and toxicity of fecal water changes
from baseline [13, 14, 18]. The mutagenicity of fecal
water will be tested using yeast as a model. The test
will be performed in exponentially growing cells,
because in these conditions cells are metabolically
active. After the treatment, cell suspensions will be
plated on complete media to detect viability and on
two different selective media (without ilv or without
trp) plates to evaluate survival and genetic effect.
 Markers of global peroxidation of fecal water
(thiobarbituric acid reactive substances [TBARs]) and
specific peroxidation of omega-3 and omega-6 poly-
unsaturated fatty acids (PUFAs) in fecal water changes
from baseline [18, 19]. The level of global and specific
peroxidation will be explored with the assay of re-
spectively free 4-hydroxy hexenal (4-HHE) and free 4-
hydroxy-2-nonenal (4-HNE). After derivatization,
HHE and HNE determinations in fecal waters will be
achieved by a sensitive and validated UHPLC-MS/MS
multiple reaction monitoring (MRM) method using
deuterated internal standards. Oxidative stress and in-
flammation are suspected to play a major role in the
pathogenesis of CRC [20, 21].
In blood we will evaluate the following:
 Lipid profile change from baseline, including total
cholesterol, low-density lipoprotein (LDL) choles-
terol, high-density lipoprotein (HDL) cholesterol,
and triglycerides
 Glycemic profile change from baseline
 Inflammatory profile change from baseline: high-
sensitivity C-reactive protein (hs-CRP), circulating
levels of inflammatory cytokines (interleukin-1ra [IL-
1ra], interleukin-1 beta [IL-1β], IL-2, IL-4, IL-6, IL-
8, IL-10, IL-12, IL-17, IL-18, tumor necrosis factor
alpha [TNFα], interferon gamma [IFNγ], vascular
endothelial growth factor [VEGF], monocyte chemo-
attractant protein-1 [MCP-1], and IFNγ-inducible
protein 10 [IP-10]).
In urine we will analyze:
 1,4-dihydroxynonane mercapturic acid (DHN-MA)
change from baseline. This specific biomarker is the
major urinary metabolite of HNE, a lipid
peroxidation product [18].
Sample size and power calculation
The sample size was determined to detect an anticipated
change in fecal water-induced DNA damage evaluated
through the comet assay of 25% from baseline, between
the MBD and the PVD interventions. On the basis of a
previously published trial conducted to test the efficacy
of a dietary intervention on fecal water-induced DNA
damage evaluated through the comet assay [14], a sam-
ple size of at least 50 in each group of the study will
allow us to obtain a statistical power of 80% (beta) and
alpha = 0.05, totaling 150 individuals. In case of loss to
follow-up, extra volunteers will be enrolled to compen-
sate. Losses will be included in the intention-to-treat but
not in the per-protocol analyses.
Recruitment and randomization
Male and female participants will be recruited using ad-
vertisements on local media, newspapers, social media,
official papers, and websites. We will also recruit from
our existing database of participants and friends or rela-
tives of the hospital and university staff. After approval
and completion of the initial assessment, the subjects
will be formally included in the study and randomized
with a simple 1:1:1 randomization to the intervention
arms through a web-based online randomization proced-
ure. No adaptive randomization procedures will be per-
formed. The random allocation sequence will be
produced and managed by an investigator who will not
take part in the participants’ recruitment. The order of
assignments will be kept hidden from the investigators
who will enroll participants or assign interventions.
Group allocation will be presented on a folded paper in
a sealed envelope.
Blinding
In this trial, blinding of participants and dieticians is not
possible because there are obvious differences between
the intervention diets. However, outcome measures in
the present study cannot be easily influenced by the ob-
server. Trial personnel who will enroll participants, data
collectors, outcome assessors, and data analysts will be
blinded to treatment allocation, and an employee outside
of the research team will input data into the computer
on separate data sheets. On the other hand, making the
trial open rather than blinded may improve recruitment.
Data collection
Follow-up assessments and data collection will be under-
taken by trial personnel at the Unit of Clinical Nutrition
of the Careggi University Hospital in Florence, Italy. All
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subjects will be examined between 6:30 and 9:30 a.m.
after a 12-h fasting period.
Compliance
Compliance with the intervention is critical to the suc-
cess of this project and will be achieved using behavior
change strategies including self-monitoring, and regular
phone calls for dietary counseling. To ensure good com-
pliance, participants will be given a detailed 1-week
menu plan for each dietary period with all foods
expressed in weight and/or volume measurements. Par-
ticipants will be contacted at least twice during the study
period to promote diet compliance. A dietician will
make unannounced telephone calls, and each participant
will recall his or her 24-h diet. Participants may discon-
tinue the intervention or withdraw from the study for
the following reasons: (1) at the request of the partici-
pant; (2) if the investigator considers that a participant’s
health will be compromised due to adverse events or a
concomitant illness that develops after entering the
study. Participants prematurely discontinued from the
study before the 3-month evaluation will have the base-
line clinical and laboratory evaluations performed.
Anthropometric measurements and body composition
Weight and height will be measured using a stadiometer.
Body mass index (BMI) will be calculated as weight (ki-
lograms)/height (square meters). Body composition will
be determined with a bioelectrical impedance analyzer
device (Akern, model SE 101) at the baseline and follow-
up visits.
Blood samples
Blood samples will be collected at the beginning and at
the end of each intervention phase. Blood samples will
be centrifuged at 3000 rpm for 15min, aliquoted to yield
serum, and then stored at − 80 °C until analyses. The fol-
lowing biochemical measurements will be evaluated:
complete blood count, lipid profile (total cholesterol,
LDL cholesterol, HDL cholesterol, triglycerides), fasting
glucose, liver function tests (aspartate aminotransferase,
alanine transaminase, gamma-glutamyl transferase),
renal function tests (serum creatinine, urea, uric acid),
mineral profile (sodium, potassium, magnesium, cal-
cium), iron metabolism (iron, ferritin), vitamin profile
(vitamin B12, folic acid), pro- and anti-inflammatory
profile (hs-CRP), and circulating levels of inflammatory
cytokines (IL-1ra, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12, IL-17, IL-18, TNFα, IFNγ, VEGF, MCP-1, and IP-10).
All the cytokines will be determined with the Bio-Plex
cytokine assay (Bio-Rad Laboratories Inc., Hercules, CA,
USA), according to the manufacturer’s instructions.
Stool samples
Stool samples (four or five scoops totaling 4 g) will be
collected before and after each intervention phase. Stool
sample collection kits, including containers, will be pro-
vided for the participant. The following stool measure-
ments will be evaluated: fecal microbiota profiles
(bacteria and fungi), targeted metabolomic profiles
(SCFAs, amino acids, and secondary bile acids such as
deoxycholic acid), genotoxicity and cytotoxicity of fecal
water (on normal and preneoplastic colon epithelial
cells), mutagenicity of fecal water (yeast model), markers
of global peroxidation of fecal water (heme, TBARs), and
markers of specific peroxidation of omega-3 and omega-
6 PUFAs in fecal water.
Storage of biological specimens
The storage of biological specimens will be performed
under appropriate conditions, according to standard
methods. Blood samples will be aliquoted and stored at
− 20 °C for 4 years before being used or destroyed. The
stored samples will be used exclusively for research pur-
poses upon consent of the donor. The destruction of
samples will be appropriately documented.
Data management
Data will be collected on an electronic database. Identifi-
able data or other documents will not be recorded in the
database, and participants will be identified by a unique
trial ID only. Hard copies of data sheets linking the par-
ticipants’ ID numbers to their contact details will be kept
securely in a locked filing cabinet in a locked office, ac-
cessible only to key research team members. Participant
files and other source data (including copies of proto-
cols, questionnaires, original reports of test results, cor-
respondence, records of informed consent, and other
documents pertaining to the conduct of the study) will
be kept for the maximum period of time permitted by
the institution. All of the project data will be stored in
the Data Sharing In Nutrition (DASH-IN) infrastructure,
which is developed by the European Nutritional Pheno-
type Assessment and Data Sharing Initiative (ENPA-
DASI). Thereby we will adhere to the FAIR principles
(Findable, Accessible, Interoperable, and Reusable). The
data will be made open access upon publication. Within
Europe the ELIXIR infrastructure is coordinating data
stewardship and management activities in the life
sciences.
Multiple strategies will be employed to improve data
quality during data collection, including an accurate re-
cruitment, a structured and time-limited protocol, the
inclusion of a run-in period, the limitation of the burden
and inconvenience of data collection on the participants,
the development of a trusting and collaborative
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relationship between research units and participants,
and double data entry.
Statistical analysis
Outcomes will be analyzed by intention-to-treat and on-
treatment procedures. The primary outcome (fecal water
genotoxicity) will be analyzed within each group using
paired comparison t tests to evaluate whether the
changes from baseline to 3 months will be statistically
significant. The absolute change (mean value at baseline
subtracted from the mean value after intervention for
each subject) will be estimated with independent t sam-
ple tests. One-way analysis of variance will be used for
testing differences between changes in the three diet
groups. A general linear model for repeated measure-
ments (after checking regression assumptions) will be
performed in order to compare the effects of the three
different treatments. A model with adjustments for mul-
tiple confounders will be used. Data for the general lin-
ear model will be reported as geometric means with
their standard errors. Multiple strategies will be
employed to reduce attrition, including an accurate re-
cruitment, a structured and time-limited protocol, the
inclusion of a run-in period, the limitation of the burden
and inconvenience of data collection on the participants,
and the development of a trusting and collaborative rela-
tionship between research units and participants. If a
participant does not attend a scheduled appointment, a
maximum of three telephone calls will be made and one
email sent prior to withdrawing the participant from the
study. If a participant wants to withdraw from the study
intervention, the reason for withdrawal will be docu-
mented in the participant records for the subsequent
analysis in the interpretation of the results.
Before starting the data analysis, the level, pattern, and
likely causes of the missingness in the baseline variables
and outcomes will be investigated by forming appropri-
ate tables. This information will be used to determine
whether the level and type of missing data have the po-
tential to introduce bias into the analysis results or sub-
stantially reduce the precision of estimates for the
proposed statistical methods. Sensitivity analyses will be
undertaken, based on the assumption that missing out-
comes are the worst possible, or the best possible, in dif-
ferent randomization groups. If these analyses show that
conclusions may differ based on missing values, then
supplementary multiple imputation for missing values
will be undertaken. These analyses will account for re-
sults of any losses to follow-up insofar as they pertain to
differences in measured variables (i.e., under the as-
sumption of missing at random). A p value < 0.05 will be
considered statistically significant. Statistical analyses
will be performed using SPSS software for Macintosh
(SPSS Inc., Chicago, IL, USA).
Monitoring
Given the limited objectives and its short-term nature, this
trial will be monitored on a regular basis by the protocol
team and the local Institutional Review Board, without the
use of a formal data monitoring committee. Each month,
the protocol team will provide the local Institutional Review
Board with a monitoring report, including a review of activ-
ities, progress, difficulties, and issues of concern. No interim
analysis will be performed. Data access will be restricted to
trained staff with unique password-protected accounts. Ad-
verse events such as unfavorable and unintended signs,
abnormal laboratory findings, symptoms, or diseases tem-
porally associated with the intervention diet will be col-
lected from the time of randomization until the final 3
months follow-up visit for each participant, whether or not
considered related to the intervention study. All adverse
events will be followed up until they are resolved.
Discussion
The Western diet typically based on red and processed
meat is considered a risk factor in colon carcinogenesis
[2]. However, although various mechanisms have been
implicated in causing this risk, it is not yet clear whether
the microbiome has a role in this process [22]. Concur-
rently, increasing evidence has been reported in the lit-
erature on the beneficial role of fish consumption on the
pathogenesis of CRC, but without convincing results [2].
In recent years, the number of subjects who have begun
to adopt a plant-based dietary pattern has increased
compared to the past, when the vegetarian population
was limited to only a few selected cohorts. This increase
is mainly attributed to ethical and environmental moti-
vations, as well as to health concerns.
To date, no studies are available that evaluate the effects
on colon carcinogenesis of a meat-based diet and a diet that
excludes meat and meat derivatives but includes fish. The
aim of the project will be to understand the role of the in-
testinal microbiota as a determinant of the effect of diet on
CRC risk and to identify specific microbiota/metabolomic
profiles associated with cancer risk. The comparison be-
tween meat-based and pesco-vegetarian dietary models in
terms of cancer risk prevention will be of fundamental clin-
ical importance for the general population and will contrib-
ute to a better understanding of the possible metabolic
mechanisms underlying the health consequences associated
with adherence to both diets in improving the neoplastic
risk profile of clinically healthy subjects.
Trial status
The trial has received all necessary regulatory approvals.
The current approved protocol version is 2.0 (version
date March 1, 2018). We anticipate a September 15,
2019 start date for recruitment and a September 15,
2020 recruitment completion date.
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